Clinical Trials Browser

Stomach Neoplasms

Thyroid Carcinoma, Anaplastic

Skin Neoplasms, Carcinoma, Merkel Cell

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

Uterine Cervical Neoplasms

Endometrial Neoplasms

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Differentiated Thyroid Cancer

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Neuroendocrine Tumors

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Carcinoma, Hepatocellular

Adenocarcinoma, Neoplasms

Ovarian Clear Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck

Uveal Melanoma, Melanoma, Neoplasm Metastasis

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

Breast Neoplasms

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma

High Grade Fallopian Tube Serous Adenocarcinoma

Uveal Melanoma, Melanoma

Carcinoma, Adenoid Cystic

Carcinoma, Renal Cell, Kidney Neoplasms

Mesothelioma, Malignant

Non-squamous Non-small-cell Lung Cancer

Carcinoma, Hepatocellular

Clinical Trials

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

Lenvatinib in Locally Advanced Invasive Thyroid Cancer

Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

PLANE-PC

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

LENVABLA

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

Neo PeLe

Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer

Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC

PLUME

Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer

Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma

Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

PEMMELA

Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma